These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8323179)

  • 21. The role of changing pulse frequency in the regulation of ovulation.
    Marshall JC; Griffin ML
    Hum Reprod; 1993 Nov; 8 Suppl 2():57-61. PubMed ID: 8276970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
    Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pituitary response to GnRH analogue testing in girls with a polycystic ovary syndrome].
    Wikiera B; Wasikowa R
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(1):13-8. PubMed ID: 16704856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pituitary and gonadal effects of GnRH (gonadotropin releasing hormone) analogues in two peripubertal female rat models.
    Roth C; Hegemann F; Hildebrandt J; Balzer I; Witt A; Wuttke W; Jarry H
    Pediatr Res; 2004 Jan; 55(1):126-33. PubMed ID: 14605254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction.
    Muenstermann U; Kleinstein J
    Hum Reprod; 2000 Dec; 15(12):2526-30. PubMed ID: 11098021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions.
    Pagán YL; Srouji SS; Jimenez Y; Emerson A; Gill S; Hall JE
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1309-16. PubMed ID: 16434454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Normal ovulatory women with polycystic ovaries have hyperandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing.
    Chang PL; Lindheim SR; Lowre C; Ferin M; Gonzalez F; Berglund L; Carmina E; Sauer MV; Lobo RA
    J Clin Endocrinol Metab; 2000 Mar; 85(3):995-1000. PubMed ID: 10720029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.
    Filicori M; Flamigni C; Campaniello E; Meriggiola MC; Michelacci L; Valdiserri A; Ferrari P
    Am J Obstet Gynecol; 1990 Nov; 163(5 Pt 2):1737-42. PubMed ID: 2122730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen response in polycystic ovarian syndrome to FSH treatment after LHRH agonist suppression.
    Hamori M; Zwirner M; Clédon P; Tinneberg HR
    Int J Fertil; 1992; 37(3):171-5. PubMed ID: 1355764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of gonadotrophin-releasing hormone agonist treatment on growth hormone secretion in women with polycystic ovarian syndrome.
    Kaltsas T; Pontikides N; Krassas GE; Seferiadis K; Lolis D; Messinis IE
    Hum Reprod; 1998 Jan; 13(1):22-6. PubMed ID: 9512222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
    Genazzani AD; Battaglia C; Gamba O; Petraglia F; Malavasi B; Genazzani AR
    J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alterations in gonadotropin-releasing hormone-dependent gonadotropin secretion in rats with polycystic ovaries.
    Carrière PD; Brawer JR; Farookhi R
    Biol Reprod; 1991 Nov; 45(5):685-90. PubMed ID: 1661616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Women with oligo-/amenorrhoea and polycystic ovaries have identical responses to GnRH stimulation regardless of their androgen status: comparison of the Rotterdam and Androgen Excess Society diagnostic criteria.
    Lewandowski KC; Cajdler-Luba A; Bieńkiewicz M; Lewiński A
    Neuro Endocrinol Lett; 2011; 32(6):847-56. PubMed ID: 22286802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of ovulation with pulsatile subcutaneous administration of human menopausal gonadotropin in patients with polycystic ovary syndrome.
    Nakamura Y; Yamada H; Yoshida K; Manno T; Ubukata Y; Suzuki M; Yoshimura Y
    Horm Res; 1990; 33 Suppl 2():43-8. PubMed ID: 2128881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovulatory disorders in women with polycystic ovary syndrome.
    Franks S; Adams J; Mason H; Polson D
    Clin Obstet Gynaecol; 1985 Sep; 12(3):605-32. PubMed ID: 3933879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.
    Corenthal L; Von Hagen S; Larkins D; Ibrahim J; Santoro N
    Fertil Steril; 1994 Jun; 61(6):1027-33. PubMed ID: 8194612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocrine response determines the clinical outcome of pulsatile gonadotropin-releasing hormone ovulation induction in different ovulatory disorders.
    Filicori M; Flamigni C; Meriggiola MC; Ferrari P; Michelacci L; Campaniello E; Valdiserri A; Cognigni G
    J Clin Endocrinol Metab; 1991 May; 72(5):965-72. PubMed ID: 1902487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of ovulation after gnRH antagonists.
    Ron-El R; Raziel A; Schachter M; Strassburger D; Kasterstein E; Friedler S
    Hum Reprod Update; 2000; 6(4):318-21. PubMed ID: 10972519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.